Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania

作者
Ștefana Bucur,E.D. Serban,Bogdan Vasile Ileanu,Raluca Costache,Alin Codruț Nicolescu,Traian Constantin,Daniel O. Costache,María Magdalena Constantin
出处
期刊:Psoriasis : Targets and Therapy [Dove Medical Press]
卷期号:Volume 14: 79-86 被引量:4
标识
DOI:10.2147/ptt.s456393
摘要

Purpose: Multiple biological therapies have been developed for the treatment of inflammatory diseases, including moderate to severe plaque psoriasis. Choosing the optimal treatment for psoriasis can depend on several factors and is strongly influenced by a drug's efficacy and safety profile. Continuous treatment with biological therapies is recommended to achieve effective disease management in patients with psoriasis. However, in real-world, patients often discontinue biologic therapy within the first year of treatment. Therefore, in this study, we aimed to investigate the effectiveness and drug survival of two anti-interleukin 17 agents (ixekizumab and secukinumab) in a group of adult patients with moderate to severe psoriasis from Bucharest, Romania. Patients and Methods: We designed an observational, non-interventional, retrospective study of 255 adult patients with moderate to severe psoriasis receiving ixekizumab and secukinumab. We performed descriptive statistics and inferential methods, such as z-test, median test and Kaplan Meier curve comparison, to characterize the groups with two biological treatments. Results: Patients treated with ixekizumab had a longer drug survival compared to those treated with secukinumab with lower risks of non-persistence, discontinuation and switching therapy. Patients age-groups and psoriasis durations found to be significant factors in drug survival. Conclusion: This study contributes to the understanding of the drug survival profile and the factors that may influence it in ixekizumab and secukinumab treatment in a real-world setting.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
搞怪的老九的应助被木子采纳,获得10
1秒前
2秒前
ding的应助被自觉的以寒采纳,获得10
3秒前
3秒前
DW的应助被寻找论文的研究生a采纳,获得10
3秒前
我不是驴熊完成签到,获得积分10
3秒前
天天快乐的应助被33采纳,获得10
4秒前
英姑的应助被小小研究僧采纳,获得10
4秒前
5秒前
思源的应助被COCO采纳,获得10
5秒前
tutu发布了新的文献求助10
6秒前
甜菜燃发布了新的文献求助10
6秒前
7秒前
AA发布了新的文献求助10
8秒前
希望天下0贩的0的应助被asd2221采纳,获得10
8秒前
ddt发布了新的文献求助10
9秒前
9秒前
儒雅的冷梅完成签到,获得积分10
9秒前
渣渣灰完成签到,获得积分10
10秒前
ocean发布了新的文献求助10
10秒前
荼蘼发布了新的文献求助10
10秒前
10秒前
柠檬完成签到,获得积分10
11秒前
二柱子完成签到 ,获得积分10
11秒前
12秒前
笑点低的凝阳完成签到,获得积分10
13秒前
14秒前
甜菜燃完成签到,获得积分10
14秒前
14秒前
愉快的真发布了新的文献求助50
14秒前
Zzzz完成签到 ,获得积分10
15秒前
15秒前
爱听歌秋尽完成签到,获得积分10
16秒前
16秒前
Eli发布了新的文献求助10
17秒前
17秒前
可爱的函函的应助被Serendipity采纳,获得10
17秒前
tutu发布了新的文献求助10
18秒前
ddt完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241